» Articles » PMID: 36551536

Correlation Between ADC Histogram-Derived Metrics and the Time to Metastases in Resectable Pancreatic Adenocarcinoma

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Dec 23
PMID 36551536
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A non-invasive method to improve the prognostic stratification would be clinically beneficial in patients with resectable pancreatic adenocarcinoma (PDAC). The aim of this study was to correlate conventional magnetic resonance (MR) features and the metrics derived from the histogram analysis of apparent diffusion coefficient (ADC) maps, with the risk and the time to metastases (TTM) after surgery in patients with PDAC. Methods: pre-operative MR examinations of 120 patients were retrospectively analyzed. Patients were grouped according to the presence (M+) or absence (M−) of metastases during follow-up. Conventional MR features and histogram-derived metrics were compared between M+ and M− patients using the Fisher’s or Mann−Whitney tests; receiver operating characteristic (ROC) curves were constructed for the features that showed a significant difference between groups. A Cox regression analysis was performed to identify the features with a significant effect on the TTM, and Kaplan−Meier curves were constructed for significant features. Results: 68.3% patients developed metastases over a mean follow-up time of 29 months (range, 3−54 months). ADC skewness and kurtosis were significantly higher in M+ than in M− patients (p < 0.001). Skewness had a significant effect on the risk of metastases (hazard ratio—HR = 5.22, p < 0.001). Patients with an ADC skewness ≥0.23 had a significantly shorter TTM than those with a skewness <0.22 (11.7 vs. 30.8 months, p < 0.001). Conclusions: pre-operative histogram analysis of ADC maps provides parameters correlated to the metastatic potential of PDAC. Higher ADC skewness seems to be associated with a significantly shorter TTM in patients with resectable PDAC.

Citing Articles

Feasibility of ADC histogram analysis for predicting of postoperative recurrence in aggressive spinal tumors.

Wang Q, Chen Y, Zhou G, Wang T, Fang J, Liu K J Bone Oncol. 2025; 51:100666.

PMID: 40028630 PMC: 11871475. DOI: 10.1016/j.jbo.2025.100666.


Volumetric histogram analysis of amide proton transfer-weighted imaging for predicting complete tumor response to neoadjuvant chemoradiotherapy in locally advanced rectal adenocarcinoma.

Yuan W, Lv X, Zhao J, Jia Z, Zhou Q, Zhang H Eur Radiol. 2024; .

PMID: 39623065 DOI: 10.1007/s00330-024-11220-6.


Use of Vascular Shunt at the Time of Pancreatectomy with Venous Resection: A Systematic Review.

Libia A, Marchese T, DUgo S, Piscitelli P, Castellana F, Clodoveo M Cancers (Basel). 2024; 16(13).

PMID: 39001423 PMC: 11240683. DOI: 10.3390/cancers16132361.


Editorial for Special Issue on Imaging Biomarker in Oncology.

Polici M, Laghi A, Caruso D Cancers (Basel). 2023; 15(4).

PMID: 36831414 PMC: 9954371. DOI: 10.3390/cancers15041071.

References
1.
Pappalardo A, Giunta E, Tirino G, Pompella L, Federico P, Daniele B . Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. Front Oncol. 2021; 11:695627. PMC: 8415474. DOI: 10.3389/fonc.2021.695627. View

2.
Neoptolemos J, Palmer D, Ghaneh P, Psarelli E, Valle J, Halloran C . Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017; 389(10073):1011-1024. DOI: 10.1016/S0140-6736(16)32409-6. View

3.
Hoffman D, Ream J, Hajdu C, Rosenkrantz A . Utility of whole-lesion ADC histogram metrics for assessing the malignant potential of pancreatic intraductal papillary mucinous neoplasms (IPMNs). Abdom Radiol (NY). 2016; 42(4):1222-1228. DOI: 10.1007/s00261-016-1001-7. View

4.
Igarashi T, Shiraishi M, Watanabe K, Ohki K, Takenaga S, Ashida H . 3D quantitative analysis of diffusion-weighted imaging for predicting the malignant potential of intraductal papillary mucinous neoplasms of the pancreas. Pol J Radiol. 2021; 86:e298-e308. PMC: 8186307. DOI: 10.5114/pjr.2021.106427. View

5.
Ducreux M, Cuhna A, Caramella C, Hollebecque A, Burtin P, Goere D . Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v56-68. DOI: 10.1093/annonc/mdv295. View